Extrait

To demonstrate superiority in the overall survival (OS) of patients with progressive mCRPC treated with sunitinib plus prednisone (SP) versus placebo plus prednisone (PP) after failure of a docetaxel-based chemotherapy regimen.

Critère d'inclusion

• Progressive metastatic castration-resistant prostate cancer after failure of a Docetaxel-based chemotherapy regimen

Liens

• euctr
• ictrp
• ictrp
• euctr
• ictrp
• euctr
• euctr
• euctr
• euctr
• euctr
• ictrp
• ictrp
• euctr
• euctr
• ictrp
• ictrp
• euctr
• euctr
• ictrp
• ictrp
• ictrp
• ictrp
• euctr